This 7% Yielding Stock Just Raised Its Profit Forecast. Is It Time to Buy?

Incoming patent cliffs regarding some of Pfizer's (NYSE: PFE) largest revenue streams have been pressuring the pharmaceutical stock. The price is down, but its dividend payout keeps rising. Last December, the company raised its quarterly payout for the 16th consecutive year.The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market closed on Aug. 5, 2025. Reliable dividend-paying stocks like Pfizer generally don't offer yields this high unless there's a reason to be concerned about the underlying business.While the company should have no problem keeping up with its 16-year-long dividend-raising streak in the near term, upcoming patent cliffs could make dividend raises unusually challenging a few years down the road. Here's a look at Pfizer's recent performance in light of the long-term challenges it faces to see if it's a good dividend stock to buy now.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool